Nov 21, 2016 07:30 AM Ligand Partner Retrophin Reports Additional Positive Data from Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis at ASN Kidney Week 2016 Nov 21, 2016 06:42 AM Roth Capital …
Trade what you see, not what you believe. The strength in the averages and leaders may ... Among the names, Ligand Pharmaceuticals LGND, +0.05% is a rare leader that sets up in a base, this one of five weeks. The developer of drugs …
Halozyme Therapeutics (HALO): Barclays trims the stock to Equal Weight from Overweight. Ligand Pharmaceuticals (LGND): LGND is lowered to Sell from Hold at Cantor Fitzgerald due to valuation. Its amended price objective is $37. …
For the past months, Insider Monkey, your source for free insider trading data, has been compiling the list of stocks that several insiders are buying like crazy ... stock appreciates as consumer sentiment and spending improves. 3. Ligand …
Analysts are weighing in on Applied Optoelectronics Inc (AAOI), Ligand Pharmaceuticals Inc. (LGND) and Momenta …
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has entered into a definitive merger agreement to acquire Pharmacopeia (NASDAQ: PCOP) in a deal valued up to $70 million. The transaction is structured as a stock-for-stock
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that ... In connection with the reverse split, Ligand also proportionately reduced the number of its authorized shares of common stock from 200.0 million to …
The biotech stock slingshot: Optimism about growth and M&A speculation ... small cap biotechs such as Emergent BioSolutions (EBS) and Ligand (LGND) as well as biotech blue chips Biogen and Celgene. Still, investors must …
Follow Ligand on Twitter @Ligand_LGND. Forward-Looking Statements This news release contains ... The failure to …